159 related articles for article (PubMed ID: 12234168)
41. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
[TBL] [Abstract][Full Text] [Related]
42. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
Aurlien E; Holte H; Pharo A; Kvaløy S; Jakobsen E; Smeland EB; Kvalheim G
Bone Marrow Transplant; 1998 May; 21(9):873-8. PubMed ID: 9613778
[TBL] [Abstract][Full Text] [Related]
43. Factors determining pbsc mobilization efficiency and nonmobilization following ICE with or without rituximab (R-ICE) salvage therapy for refractory or relapsed lymphoma prior to autologous transplantation.
Xia W; Ma CK; Reid C; Bai L; Wong K; Kerridge I; Ward C; Greenwood M
J Clin Apher; 2014 Dec; 29(6):322-30. PubMed ID: 24944079
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of mobilized peripheral stem cells according to CD34 and aldehyde dehydrogenase expression and effect of SSC(lo) ALDH(br) cells on hematopoietic recovery.
Gündüz E; Demirel G; Bal C; Gulbas Z
Cytotherapy; 2010 Dec; 12(8):1006-12. PubMed ID: 20735165
[TBL] [Abstract][Full Text] [Related]
45. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience.
Olivieri A; Offidani M; Montanari M; Ciniero L; Cantori I; Ombrosi L; Masia CM; Centurioni R; Mancini S; Brunori M; Leoni P
Haematologica; 1998 Apr; 83(4):329-37. PubMed ID: 9592983
[TBL] [Abstract][Full Text] [Related]
46. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
[TBL] [Abstract][Full Text] [Related]
47. A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma.
Arcaini L; Orlandi E; Alessandrino EP; Iacona I; Brusamolino E; Bonfichi M; Bernasconi P; Calatroni S; Tenore A; Montanari F; Troletti D; Pascutto C; Regazzi M; Lazzarino M
Bone Marrow Transplant; 2004 Jul; 34(2):175-9. PubMed ID: 15170171
[TBL] [Abstract][Full Text] [Related]
48. Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study.
Belhadj K; Delfau-Larue MH; Elgnaoui T; Beaujean F; Beaumont JL; Pautas C; Gaillard I; Kirova Y; Allain A; Gaulard P; Farcet JP; Reyes F; Haioun C
Ann Oncol; 2004 Mar; 15(3):504-10. PubMed ID: 14998857
[TBL] [Abstract][Full Text] [Related]
49. Hematopoietic stem cells from poor and good mobilizers are qualitatively equivalent.
Jiang L; Malik S; Litzow M; Gastineau D; Micallef I; Roy V; Solberg L; Zubair AC
Transfusion; 2012 Mar; 52(3):542-8. PubMed ID: 21827503
[TBL] [Abstract][Full Text] [Related]
50. CD34+ subset and tumor cell quantitation by flow cytometry--step toward quality assessment of autografts in B cell malignancies.
Johnsen HE; Rasmussen T; Knudsen LM
Vox Sang; 1998; 74 Suppl 2():477-82. PubMed ID: 9704485
[TBL] [Abstract][Full Text] [Related]
51. Autografting with peripheral blood stem cells mobilized by sequential interleukin-3/granulocyte-macrophage colony-stimulating factor following high-dose chemotherapy in non-Hodgkin's lymphoma.
Haas R; Ehrhardt R; Witt B; Goldschmidt H; Hohaus S; Pförsich M; Ehrlich H; Färber L; Hunstein W
Bone Marrow Transplant; 1993 Dec; 12(6):643-9. PubMed ID: 7511017
[TBL] [Abstract][Full Text] [Related]
52. Poor lymphocyte recovery following CD34-selected autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.
Diviné M; Boutolleau D; Delfau-Larue MH; Beaujean F; Jouault H; Reyes F; Kuentz M; Bensussan A; Farcet JP; Boumsell L
Br J Haematol; 1999 May; 105(2):349-60. PubMed ID: 10233403
[TBL] [Abstract][Full Text] [Related]
53. Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma.
Lemoli RM; Rosti G; Visani G; Gherlinzoni F; Miggiano MC; Fortuna A; Zinzani P; Tura S
J Clin Oncol; 1996 Nov; 14(11):3018-25. PubMed ID: 8918500
[TBL] [Abstract][Full Text] [Related]
54. Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells.
Stockerl-Goldstein KE; Reddy SA; Horning SF; Blume KG; Chao NF; Hu WW; Johnston LF; Long GD; Strober S; Wong RM; Feiner RH; Kobler S; Negrin RS
Biol Blood Marrow Transplant; 2000; 6(5):506-12. PubMed ID: 11063379
[TBL] [Abstract][Full Text] [Related]
55. Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL.
Flohr T; Hess G; Kolbe K; Gamm H; Nolte H; Stanislawski T; Huber C; Derigs HG
Bone Marrow Transplant; 2002 May; 29(9):769-75. PubMed ID: 12040475
[TBL] [Abstract][Full Text] [Related]
56. High-dose fractionated total-body irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: comparison of autologous bone marrow and peripheral blood stem cells.
Brunvand MW; Bensinger WI; Soll E; Weaver CH; Rowley SD; Appelbaum FR; Lilleby K; Clift RA; Gooley TA; Press OW; Fefer A; Storb R; Sanders JE; Martin PL; Chauncey T; Maziarz RT; Zuckerman N; Montgomery P; Dorn R; Weiden PL; Demirer T; Holmberg LA; Schiffman K; McSweeney PA; Buckner CD
Bone Marrow Transplant; 1996 Jul; 18(1):131-41. PubMed ID: 8832006
[TBL] [Abstract][Full Text] [Related]
57. Prediction of delayed platelet engraftment after autologous stem cell transplantation for B-cell non-Hodgkin lymphoma.
Yamaguchi J; Chinen Y; Takimoto-Shimomura T; Nagata H; Muramatsu A; Kuriyama K; Ohshiro M; Hirakawa Y; Iwai T; Uchiyama H; Uoshima N; Kaneko H; Nakao M; Tsukamoto T; Shimura Y; Kobayashi T; Horiike S; Yokota I; Kuroda J;
Leuk Lymphoma; 2019 Dec; 60(14):3434-3441. PubMed ID: 31318305
[TBL] [Abstract][Full Text] [Related]
58. High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma.
Hosing C; Saliba RM; Körbling M; Acholonu S; McMannis J; Anderlini P; Giralt S; De Lima M; Okoroji GJ; Couriel DR; Champlin R; Khouri IF; Donato ML
Leuk Lymphoma; 2006 Jul; 47(7):1290-4. PubMed ID: 16923559
[TBL] [Abstract][Full Text] [Related]
59. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
60. Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma.
Donato ML; Champlin RE; Van Besien KW; Korbling M; Cabanillas F; Anderlini P; Gajewski JG; Lauppe J; Durett A; Andersson B; Giralt S; Khouri I; Hagemeister F; Romaguera JE; Sarris A; McLaughlin P; Younes A; Ippoliti C; Blamble DA; Hester J; Gee A; Rodriguez MA
Leuk Lymphoma; 1999 Oct; 35(3-4):317-24. PubMed ID: 10706456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
